SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, ...

Core Viewpoint - Moderna has experienced a significant decline in stock performance and sales due to waning demand for its coronavirus vaccine, losing over 90% of its value since its peak in 2021 [1][2][7] Company Background - Moderna initially gained prominence during the pandemic, generating up to $18.4 billion in annual revenue from its coronavirus vaccine, leading to substantial profits [4] - The company has since faced challenges as vaccine demand decreased, and its RSV vaccine sales have also underperformed [5] Cost Management and R&D Focus - In response to declining sales, Moderna has initiated a cost realignment plan aiming to reduce GAAP operating costs by up to $1.7 billion by 2027 [6] - The company is prioritizing research and development, with plans to launch as many as 10 new products in the next three years, although these launches are not guaranteed [6] Future Product Pipeline - Moderna anticipates having around 10 products on the market in 10 years, including several cancer vaccines and a cytomegalovirus vaccine, along with potential respiratory virus vaccines [11] - The company has a strong success rate in late-stage trials, with an 83% probability of success in phase 3 trials compared to the industry average of 69% [12] Revenue Projections - By 2028, Moderna expects to break even on an operating cash cost basis and generate $6 billion in revenue, with new product launches from 2026 to 2028 projected to yield a compounded annual growth rate of 25% or more [12] - Even with partial success in product launches, Moderna could achieve significant revenue growth over the next decade [13]

Anixa Biosciences (ANIX) Update Summary Company Overview - Anixa Biosciences was reinvented in 2017 as a biotechnology company focusing on cancer therapies, with a robust pipeline of products currently in clinical trials [5][6] - The company has established partnerships with leading organizations such as the Cleveland Clinic and Moffitt Cancer Center, and receives funding from the U.S. Department of Defense and the National Cancer Institute [6][7] Financial Position - Anixa maintains a strong balance sheet with over two years of cash on hand, allowing for significant clinical milestones without frequent capital raises [8][12] - The company has a clean capital structure with 32 million shares of common stock and no warrants or preferred stock [10][11] Clinical Programs CAR T Therapy for Ovarian Cancer - The CAR T therapy targets terminally ill ovarian cancer patients and is currently in clinical trials at Moffitt Cancer Center [17][19] - The therapy utilizes a unique target, the follicle stimulating hormone receptor (FSHR), which is only found on ovarian cells and tumor blood vessels, allowing for a dual mechanism of action [29][31] - Early results show promising outcomes, with some patients living significantly longer than expected [39][41] - The FDA has approved the possibility of administering a second dose to patients showing initial responses, which is a rare approval for CAR T therapies [41][80] Breast Cancer Vaccine - The breast cancer vaccine aims to treat and prevent breast cancer, particularly targeting triple-negative breast cancer [42][43] - The vaccine is based on the alpha lactalbumin protein, which is produced during lactation and is found in many breast cancer cells [43][44] - Initial Phase I trials have shown strong immune responses and safety, with plans for a Phase II trial to compare the vaccine's effectiveness against standard care [51][55] - The vaccine has the potential to change the paradigm of cancer prevention, aiming for primary prevention in women without a history of cancer [59][60] Market Opportunities - Anixa is addressing large markets, including breast and ovarian cancer, with plans to expand into lung, prostate, and colon cancer [7][20][61] - The company anticipates significant market opportunities if their therapies prove successful, particularly in the context of the breast cancer vaccine [58][61] Strategic Partnerships and Funding - Discussions with potential pharmaceutical partners for both the CAR T therapy and breast cancer vaccine are ongoing, with hopes for fruitful collaborations in the near future [68] - The U.S. Department of Defense has funded the breast cancer vaccine study, recognizing its potential to change cancer treatment landscapes [70][71] Key Milestones and Future Outlook - Upcoming milestones include comprehensive clinical data presentations at the San Antonio Breast Cancer Conference and ongoing updates on patient outcomes for the CAR T therapy [64][66] - The company is optimistic about the potential for partnerships and funding based on the promising early results from their clinical trials [68][86]

Summary of Alessio Therapeutics Virtual KOL Event Company and Industry - **Company**: Alessio Therapeutics - **Industry**: Cancer Immunotherapy, specifically focusing on pancreatic cancer and KRAS-driven therapies Core Points and Arguments 1. **Introduction of ELI O2 Vaccine**: The event discussed the ELI O2 cancer vaccine aimed at treating mutant KRAS-driven pancreatic cancer, highlighting its innovative approach to cancer vaccination [2][3][32] 2. **Challenges in Cancer Vaccines**: The speakers outlined significant challenges faced by cancer vaccines, including selecting suitable antigens, poor potency in humans, and difficulties in targeting the immune system's command center, the lymph nodes [6][10][12] 3. **Amplify Platform**: The Amplify platform was introduced as a solution to enhance vaccine performance by utilizing lymph node targeting, which is crucial for effective immune response [4][32] 4. **Preclinical Studies**: Preclinical studies demonstrated that the AMP vaccines significantly improved lymph node targeting and T cell activation compared to traditional peptide vaccines, showing a potential increase in immunogenicity [20][30][32] 5. **Clinical Development**: The clinical program for ELI O2 is designed to assess safety, immunogenicity, and clinical outcomes in patients with pancreatic cancer, with a focus on KRAS mutations [55][68] 6. **Neoadjuvant and Adjuvant Therapy**: The discussion included the importance of neoadjuvant therapy in pancreatic cancer, which can shrink tumors and facilitate better surgical outcomes [42][43] 7. **KRAS Targeting**: The significance of KRAS mutations in pancreatic cancer was emphasized, with ongoing research into small molecule inhibitors and immunotherapies targeting these mutations [50][70] Additional Important Content 1. **Immunogenicity and Biomarker Response**: The ELI O2 vaccine showed promising results in inducing T cell responses and reducing circulating tumor DNA (ctDNA) levels in early studies, indicating potential clinical benefits [56][65] 2. **Safety Profile**: The vaccine demonstrated a manageable safety profile with mild side effects, which is crucial for patient acceptance and adherence [68] 3. **Future Directions**: The potential for combining ELI O2 with other therapies, including immune checkpoint inhibitors and chemotherapy, was discussed as a strategy to enhance treatment efficacy [70][71] 4. **Regulatory Considerations**: The design of the phase two and phase three trials was discussed, with a focus on disease-free survival as a primary endpoint, reflecting the regulatory landscape for cancer therapies [72] This summary encapsulates the key discussions and findings presented during the Alessio Therapeutics Virtual KOL Event, focusing on the innovative approaches to cancer vaccination and the specific challenges and opportunities within the pancreatic cancer treatment landscape.

Forward-Looking Statements and Intended Use This presentation and the accompanying verbal remarks contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding data and results from clinical trials and potential implications therefrom, commercialization plans and timelines, including product availability and shipments, potential regulatory pathways and approval requests and submissions, FDA and other regulatory agency meetings, ti ...

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].

Core Insights - Moderna's stock has experienced a decline of over 80% in the past year, primarily due to reduced vaccine sales and a disappointing outlook [1][2] - The company reported a significant drop in revenue, with a decrease of 83% from $18.9 billion in 2022 to $3.1 billion over the last twelve months [3] - Moderna's narrow product portfolio has made it vulnerable to demand fluctuations, especially as it transitions from a pandemic-driven market to a seasonal vaccine market [5][7] Financial Performance - Moderna's operating income over the past four quarters was -$3.7 billion, resulting in an operating margin of -118.8% [6] - The operating cash flow during the same period was -$3.1 billion, indicating a low cash flow margin of -97.2% [6] - The company's sales forecast for 2025 was cut by $1 billion, and the break-even target was delayed by two years due to development setbacks [4] Market Transition - The demand for Moderna's COVID-19 vaccine has significantly decreased as the pandemic has shifted to an endemic stage, impacting sales [2][7] - The company is attempting to diversify its revenue sources, but the rapid decline in COVID-19 vaccine sales has outpaced its efforts to compensate for these losses [7] - Promising clinical trial results for a skin cancer vaccine exist, but its rollout is still years away pending regulatory approvals [5]

SAN JOSE, Calif., June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends." Both the New York Post and Fox News highlighted the potential of Anixa's vaccine to change the paradigm for breast cancer tr ...

Moderna (MRNA) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Everyone, thank you. Good morning, and thank you for joining us on our next discussion here at the Jefferies Healthcare Conference. I have the pleasure of having the President of Moderna, Stephen Hoag, up here with us. Obviously, timely. A lot's going on in the world, both from a regulatory administrative standpoint. We had Marty Makary here yesterday. Obviously, a lot going on with your commercial business, the pipeline, all of that. So I lo ...

Evaxion Biotech (EVAX) Q1 2025 Earnings Call May 27, 2025 08:30 AM ET Company Participants Christian Kanstrup - Chief Executive OfficerBirgitte Rønø - Chief Scientific OfficerThomas Schmidt - CFO Conference Call Participants Thomas Flaten - Senior Research Analyst Operator Good day, and thank you for standing by. Welcome to the Evaction First Quarter twenty twenty five Conference Call and Webcast. At this time, all participants are in listen only mode. After the speakers' presentation, there will be the que ...